A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis

Phase 2

Completed

• Conditions: Hyperhidrosis
• Interventions: Drug: glycopyrrolate, 2.0%; Other: Vehicle; Drug: glycopyrrolate, 1.0%; Drug: glycopyrrolate, 3.0%; Drug: glycopyrrolate, 4.0%

• Registration Number: NCT02016885
• Lead Sponsor: Journey Medical Corporation

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of glycopyrrolate compared to vehicle for the treatment of axillary hyperhidrosis.

Detailed Description

This is a randomized, vehicle controlled, dose-ranging study enrolling subjects with axillary hyperhidrosis and designed to assess the safety and efficacy of four doses of glycopyrrolate compared to vehicle. There are 5 arms in this study.

Efficacy will be assessed through the Hyperhidrosis Disease Severity Score (HDSS), Dermatology Life Quality Index (DLQI) and a gravimetric assessment of sweat production.

Safety will be assessed, at specified times during the study, through adverse events, local skin responses, serum chemistry and hematology laboratory testing, ECGs, physical examination and vital signs.

PK samples will be taken from 20 to 30 subjects participating in the study.

Study Timeline

• Study Start: 2013-11
• Study First Submitted: 2013-12-16
• Study First Submitted QC: 2013-12-16
• Study First Posted: 2013-12-20
• Primary Completion: 2014-09
• Study Completion: 2014-09
• Disposition First Submitted: 2015-10-22
• Disposition First Submitted QC: 2015-10-22
• Disposition First Posted: 2015-11-13
• Results First Submitted: 2018-07-17
• Results First Submitted QC: 2018-09-11
• Results First Posted: 2018-09-13
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-23
• Last Update Posted: 2021-08-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 198

Inclusion Criteria

• Male or female, 18 years of age or older.
• Primary, axillary hyperhidrosis of at least 6 months duration.
• A Hyperhidrosis Disease Severity Score (HDSS) of 3or 4.
• A gravimetric measurement of sweat production of at least 50 mg over 5 minutes in each axilla (total of 100 mg) while at rest at room temperature.
• Male or non-pregnant, non-lactating females.

Read More

Exclusion Criteria

• Prior surgical procedure for hyperhidrosis.
• Any prior treatment with an axillary anti-hyperhidrosis medical device (approved or investigational)
• Prior treatment with botulinum toxin for axillary hyperhidrosis within 1 year.
• Treatment with cholinergic, serotonergic antagonists, and dopamine partial agonists thought to relieve antidepressant-induced hyperhidrosis. Treatment with psychotherapeutic medications for less than 4 months prior to study enrollment. - Treatment with topical or systemic anticholinergics, adrenergic agonists (clonidine), or beta-blockers within 4 weeks prior to enrollment.
• Prior axillary treatment with axillary iontophoresis within 4 weeks.
• Axillary use of nonprescription or prescription antiperspirants within 2 weeks of study enrollment.
• Known history of a condition that may cause secondary hyperhidrosis.
• Known history of Sjögren's syndrome or Sicca syndrome.
• Abnormal findings on screening ECG deemed clinically significant by the Investigator.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
glycopyrrolate, 2.0%	glycopyrrolate, 2.0%	glycopyrrolate Topical Wipes, 2.0%
Vehicle	Vehicle	Vehicle Topical Wipes
glycopyrrolate, 1.0%	glycopyrrolate, 1.0%	glycopyrrolate Topical Wipes, 1.0%
glycopyrrolate, 3.0%	glycopyrrolate, 3.0%	glycopyrrolate Topical Wipes, 3.0%
glycopyrrolate, 4.0%	glycopyrrolate, 4.0%	glycopyrrolate Topical Wipes, 4.0%

Primary Outcome Measures

Name	Time	Method
Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4	Baseline - Week 4	HDSS is a disease specific diagnostic tool that provides a qualitative measure of the severity of the subjects' condition based on how it affects daily activities.; 1 (Best), 2, 3, 4 (Worst)
Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 4	Baseline - Week 4	Subjects are acclimated to the environment for 30 minutes. Dry gauze is weighed. The dry gauze is then applied to the subject's axilla with the arm down by the subject's side or on their lap during the 5-minute period of sweat production. The gauze with the sweat is then weighed. The difference between the Weight of the gauze with sweat and the dry gauze is the gravimetric sweat measurement in mg/5min.

Secondary Outcome Measures

Name	Time	Method
Change in Dermatology Life Quality Index (DLQI) From Baseline at Week 4	Baseline - Week 4	The DLQI is a ten question questionnaire, used to measure the impact of skin disease on the quality of life of an affected person. The scoring of each question is as follows: Very much (3), A lot (2), A little (1), Not at all (0), Not relevant (0). Is calculated by summing the score of each question resulting in a max of 30 and a min of 0. Higher the score the more Quality of life is impaired.
Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 6	Baseline - Week 6
Percentage of Subjects Who Have a Minimum 1-grade Improvement in HDSS From Baseline at Week 4	Baseline - Week 4
Absolute Change in the Gravimetrically Measured Sweat Production From Baseline to Week 6	Baseline - Week 6

Trial Locations

Locations (21)

Kenneth R. Beer, MD, PA; 🇺🇸 West Palm Beach, Florida, United States

Shideler Clinical Research Center; 🇺🇸 Carmel, Indiana, United States

Burke Pharmaceutical Research; 🇺🇸 Hot Springs, Arkansas, United States

Skin Specialists, PC; 🇺🇸 Omaha, Nebraska, United States

The Dermatology Group, PC; 🇺🇸 Verona, New Jersey, United States

Cypress Medical Research Center, LLC; 🇺🇸 Wichita, Kansas, United States

Florida Academic Dermatology Center; 🇺🇸 Miami, Florida, United States

Dermatology Research Center, Inc.; 🇺🇸 Salt Lake City, Utah, United States

Center For Dermatology Clinical Research; 🇺🇸 Fremont, California, United States

Gary M. Petrus, MD, PA; 🇺🇸 Little Rock, Arkansas, United States

California Dermatology & Clinical Research Institute; 🇺🇸 Encinitas, California, United States

Minnesota Clinical Study Center; 🇺🇸 Fridley, Minnesota, United States

Saint Louis University Dermatology; 🇺🇸 Saint Louis, Missouri, United States

J&S Studies, Inc.; 🇺🇸 College Station, Texas, United States

Clinical Trials of Texas, Inc.; 🇺🇸 San Antonio, Texas, United States

Oregon Medical Research Center; 🇺🇸 Portland, Oregon, United States

Dermatology Associates; 🇺🇸 Seattle, Washington, United States

Westend Dermatology Associates; 🇺🇸 Richmond, Virginia, United States

Virginia Clinical Research, Inc.; 🇺🇸 Norfolk, Virginia, United States

Women's Clinical Research Center; 🇺🇸 Seattle, Washington, United States

Premier Clinical Research; 🇺🇸 Spokane, Washington, United States